Positive results for Orsiro coronary drug | 合法醫療器材資訊網

Very thin strut biodegradable polymer everolimus-eluting stents versus ... Designed for challenging cases, the Orsiro stent system provides better push and​ ... Read More

The Orsiro Mission Sirolimus-Eluting Coronary Stent System is a drug-eluting balloon-expandable stent pre-mounted on a rapid-exchange PTCA catheter delivery ... Read More

2020年2月28日 — The Orsiro cobalt chromium metal stent elutes sirolimus via Biolute, Biotronik's bioabsorbable polymer coating. Beneath the bioabsorbable ... Read More

2019年2月22日 — The U.S. Food and Drug Administration (FDA) has approved the Biotronik Orsiro drug-eluting coronary stent (DES) system. Orsiro is the first ... Read More

The Orsiro Hybrid Drug-Eluting Stent brings the optimal combination of effortless deliverability, coupled with a hybrid coating for treating coronary artery stenosis. Read More

2021年3月15日 — March 15, 2021 — BIOTRONIK's ultrathin-strut stent, Orsiro®*, demonstrated superiority over Xience DES for target lesion failure (TLF) at 24 ... Read More

The rate of stent thrombosis for Orsiro was low in the BIOFLOW clinical trials and did not differ significantly from expectations for a current generation DES. The ... Read More